Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TECX

Tectonic Therapeutic Inc

35.22

Jul 06 • 04:00PM ET -2.71 (-7.14%)

Healthcare Biotechnology USA Small NASD

Peers: INCY KYMR NUVL BMRN RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VXF IWN IBB VTWO IWC VHT SBIO IWO

Scroll to Statements

Index	RUT
Market Cap	664.57M
Enterprise Value	428.96M
Income	-83.49M
Sales	0.00M
Book/sh	13.41
Cash/sh	12.55
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	60
IPO	Jun 21, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.63
P/C	2.81
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	26.63
Current Ratio	26.63
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.46
EPS next Y	-5.68
EPS next Q	-1.35
EPS this Y	-31.73%
EPS next Y	-6.43%
EPS next 5Y	-16.40%
EPS past 3/5Y	48.16% 36.65%
Sales past 3/5Y	- -
EPS Y/Y TTM	38.99%
Sales Y/Y TTM	-
EPS Q/Q	-44.87%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	-15.01% -

Insider Own	49.75%
Insider Trans	-0.14%
Inst Own	62.95%
Inst Trans	-10.16%
ROA	-29.74%
ROE	-31.42%
ROIC	-33.21%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	13.28%
SMA50	18.87%
SMA200	47.65%
Trades

Shs Outstand	18.87M
Shs Float	9.48M
Short Float	22.70%
Short Ratio	10.66
Short Interest	2.15M
52W High	38.12 -7.61%
52W Low	14.39 144.84%
Volatility	10.66% 7.19%
ATR (14)	2.34
RSI (14)	62.47
Beta	1.21
Rel Volume	1.21
Avg Volume	201.84K
Volume	244,569

Perf Week	10.10%
Perf Month	23.93%
Perf Quarter	15.40%
Perf Half Y	68.84%
Perf YTD	68.84%
Perf Year	65.04%
Perf 3Y	199.46%
Perf 5Y	-65.47%
Perf 10Y	-
Recom	1.00
Target Price	78.44
Prev Close	37.93
Price	35.22
Change	-7.14%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-26	Upgrade	Raymond James	Outperform → Strong Buy	$81
Apr-14-26	Initiated	Stifel	Buy	$75
Oct-20-25	Initiated	Wells Fargo	Overweight	$101
Sep-03-25	Initiated	Oppenheimer	Outperform	$80
Jul-21-25	Initiated	Truist	Buy	$64
Jun-11-25	Resumed	Raymond James	Outperform	$76
Apr-21-25	Initiated	Mizuho	Outperform	$51
Nov-20-24	Initiated	Raymond James	Outperform	$65
Aug-22-24	Initiated	Wells Fargo	Overweight	$55
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13

Show Previous Ratings

Jun-10-26 04:01PM	Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients (GlobeNewswire)
May-07-26 04:01PM	Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -7.41% +7.93%
Apr-23-26 04:01PM	Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors (GlobeNewswire)
Mar-02-26 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-26 04:17PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:18AM	Loading…
Feb-25-26 04:18AM	Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins (MarketBeat) +8.24%
Feb-23-26 04:01PM	Tectonic Therapeutic Appoints Francois Nader, M.D., as Chair and Independent Director of the Board (GlobeNewswire)
Feb-11-26 04:01PM	Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 (GlobeNewswire)
Dec-10-25 02:13PM	Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating (Insider Monkey)
Dec-01-25 08:00AM	Tectonic Therapeutic to Participate in December Investor Conferences (GlobeNewswire)
Nov-06-25 04:01PM	Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +15.51%
Oct-29-25 04:01PM	Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF (GlobeNewswire) -5.48%
Aug-28-25 09:00AM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-07-25 04:01PM	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -5.35%
Jun-30-25 08:00AM	Tectonic Therapeutic Joins Russell 3000 Index (GlobeNewswire)
05:42PM	Loading…
Jun-24-25 05:42PM	Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating (Insider Monkey) +7.57%
May-17-25 10:40AM	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 (GlobeNewswire)
May-13-25 09:55AM	Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? (Zacks)
May-08-25 04:01PM	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +10.81% -5.99%
May-07-25 08:00AM	Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference (GlobeNewswire)
May-01-25 05:59AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks Earning Wall Streets Seal of Approval (TipRanks) -5.75%
Apr-23-25 05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-15-25 08:00AM	Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 (GlobeNewswire)
Mar-20-25 04:01PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:26PM	Is Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-20-25 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-03-25 06:30AM	Tectonic Announces $185 Million Private Placement (GlobeNewswire) -6.52%
Jan-30-25 06:30AM	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF (GlobeNewswire) +113.22%
Dec-03-24 04:01PM	Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 (GlobeNewswire)
Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
11:01PM	Loading…
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Ph.D.Dr. Alise S. Reicin M.D.

Chief Financial OfficerMr. Daniel Lochner M.B.A.

M.S.Dr. Marcella Kuhlman Ruddy M.D.

Senior Vice President of Technical OperationsMr. Washington Alves M.S.

Chief Scientific OfficerDr. Peter McNamara Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McNamara Peter	Chief Scientific Officer	Jun 30 '26	Option Exercise	14.71	172	2,530	55,457	Jul 01 05:19 PM
McNamara Peter	Chief Scientific Officer	Jun 30 '26	Sale	35.00	172	6,020	55,285	Jul 01 05:19 PM
PETER MCNAMARA	Officer	Jun 30 '26	Proposed Sale	33.09	172	5,691		Jun 30 04:38 PM
Ruddy Marcella K.	Chief Medical Officer	May 04 '26	Sale	30.00	1,065	31,950	67,682	May 06 05:00 PM
Ruddy Marcella K.	Chief Medical Officer	Apr 01 '26	Sale	31.05	1,000	31,050	68,747	Apr 03 04:24 PM
Ruddy Marcella K.	Chief Medical Officer	Mar 06 '26	Sale	30.00	10,000	300,000	69,747	Mar 09 06:15 PM
McNamara Peter	Chief Scientific Officer	Mar 06 '26	Option Exercise	3.36	2,715	9,113	61,547	Mar 09 06:12 PM
McNamara Peter	Chief Scientific Officer	Mar 06 '26	Sale	30.17	6,262	188,935	55,285	Mar 09 06:12 PM
PETER MCNAMARA	Officer	Mar 06 '26	Proposed Sale	27.85	6,262	174,397		Mar 06 04:31 PM
MARCELLA RUDDY	Officer	Mar 06 '26	Proposed Sale	27.85	12,065	336,010		Mar 06 04:31 PM
McNamara Peter	Chief Scientific Officer	Mar 04 '26	Sale	25.00	1,650	41,250	58,832	Mar 05 05:45 PM
McNamara Peter	Chief Scientific Officer	Mar 03 '26	Sale	22.06	1,649	36,377	37,482	Mar 05 05:45 PM
PETER MCNAMARA	Officer	Mar 04 '26	Proposed Sale	24.39	1,650	40,252		Mar 04 04:42 PM
PETER MCNAMARA	Officer	Mar 03 '26	Proposed Sale	23.00	1,649	37,927		Mar 03 04:44 PM
REICIN ALISE	Chief Executive Officer	Feb 11 '26	Buy	21.10	2,500	52,750	237,547	Feb 12 04:15 PM
Schwabish Marc	Chief Business Officer	Feb 10 '26	Option Exercise	2.38	4,500	10,710	25,814	Feb 12 04:15 PM
Lochner Daniel	Chief Financial Officer	Feb 10 '26	Buy	21.61	6,000	129,660	32,044	Feb 11 05:32 PM
REICIN ALISE	Chief Executive Officer	Dec 31 '25	Option Exercise	2.38	10,966	26,099	239,151	Jan 05 05:02 PM
McNamara Peter	Chief Scientific Officer	Dec 22 '25	Option Exercise	2.98	7,000	20,860	40,879	Dec 29 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TECX

Tectonic Therapeutic Inc

Upgrade your Finviz experience